Linshom Medical, Inc. Closes $1.5 million Series A Round with Investment from Maryland Momentum Fund and Current Investors

Linshom is First to Deliver an Operating-Room-Quality Respiratory Profile to Patient Bedside for Continuous, Predictive Respiratory Monitoring (CPRM)

Baltimore, Md. (April 27, 2022) – Linshom (“to breathe”), a Maryland-based startup developing a respiratory monitoring system, closed a $1.5 million Series A funding round with investment from the Maryland Momentum Fund and current investors.  

The Linshom Respiratory Sensor and Monitor is the first predictive, continuous respiratory monitoring system able to practically reach the patients’ bedside. Severe respiratory events can begin to cause brain damage only three minutes after breathing ceases. While critical care patients are continuously monitored for respiratory function, patients on general care floors are not monitored as closely, but are still at risk for serious respiratory complications. The Linshom Respiratory System bridges that gap, helping clinicians respond more quickly to severe respiratory-related events.

“Patient respiratory depression events are fairly common in hospitals; half of all adverse events occur on general care floors and 75% of those events are respiratory in nature. Linshom can intercept these disasters by calling early attention to respiratory decline so that clinical staff can take action,” said Richard Hughen, chief executive officer of Linshom. “I am delighted to have the Maryland Momentum Fund join as an investor. The value of their commitment lies in more than just financing; it has triggered a spike of interest from other investors.”

Lack of comprehensive, portable, and inexpensive continuous respiratory monitoring at the patient’s bedside is a major gap in current standard of care. Current equipment is too big, expensive, and complex for bedside use. Linshom delivers an operating room quality respiratory profile to the patient bedside, providing clinicians with a safe, reliable, noninvasive, and simple solution for respiratory monitoring.

“We see a lot of medtech devices in Maryland and Linshom was particularly exciting,” said Claire Broido Johnson, managing director of the Maryland Momentum Fund. “The device has a clear and proven market fit and the company has already received FDA 510(k) clearance, which helps clear its path to market and ultimately to the patient bedside. In addition, Richard and his team have deep knowledge and experience in developing and commercializing medical technologies.”

Ronen Feldman, chief technology officer and co-inventor of the Linshom device, is a University of Maryland, College Park alum (’85, Mathematical and Physical Sciences and Engineering).

Linshom plans to use funding from this round to refine the existing sensor and integrate into a multi-parameter monitor. Their design partner is Harbor Designs and Manufacturing, a Baltimore-based firm. In parallel, Linshom will continue developing the evidence needed for rapid clinical adoption and commercialization through a clinical study at Brigham and Women’s Hospital.

About Linshom Medical, Inc.
Linshom (“to breathe”) is first to deliver an Operating Room quality respiratory profile to the patient bedside (or home) for continuous, predictive respiratory monitoring (CPRM). Our patented and FDA cleared device provides a predictive (vs. responsive) respiratory profile including Respiratory Rate (RR), Tidal Volume (rTV) and Seconds Since Last Breath (SSLB) that are all delivered continuously and in real time. Our mission is to eliminate the morbidity, mortality and cost due to unrecognized respiratory compromise in healthcare with the first predictive respiratory device vs. the current responsive systems used today. For more information, visit

Linshom Contact:
Richard Hughen, CEO
Phone: 443-994-1448

About the USM Momentum Fund
The Maryland Momentum Fund is an initiative of the University System of Maryland (USM) to provide late seed investment funding for promising technology ventures that come out of any of the 12 constituent USM institutions, its research parks, and its students, faculty, or graduates. With a $10M commitment from the USM already in place, the Fund co-invests with venture capitalists, foundations, and angel investors.
The Maryland Momentum Fund was established by the USM Board of Regents to support promising commercial opportunities arising from advances in research and intellectual property at USM campuses, and its portfolio companies include:
MF Fire, NextStep Robotics, the North American Wave Engine Corporation, Zest Tea, PaverGuide, Retrium, Veralox Therapeutics, Gemstone Biotherapeutics, Neoprogen, Minnowtech, ARMR Systems, Infercabuary, Datakwip, pathOtrak, KaloCyte, MiRecule, N5 Sensors, VisiSonics, Voxy EngGen, Dynamhex, TargetDocs, Qualytics, Liatris, AquaLith, GivHero, and Linshom. The Fund is designed to create returns and support USM’s most innovative ideas as they enter the marketplace. Learn more at


Contact: Mike Lurie
Phone: 301.445.2719